Veterinary OTC
[Veterinary Drug Name]
Generic name: Flunixin Meglumine Granules
Trade name:
English name: Flunixin Meglumine Granules
Pinyin: Funixin Pujia’an Keli
[Main Ingredients] Flunixin meglumine
[Description] This drug is of off-white or light yellow granules.
[Pharmacological Action] Pharmacodynamics: As a potent cyclooxygenase inhibitor, flunixin meglumine has analgesic, antipyretic, anti-inflammatory, and anti-rheumatic effects. The analgesic effect refers to blocking the transmission of pain impulses by the inhibition of the synthesis of peripheral prostaglandins or their pain sensitizers, or their combined action. The anti-inflammatory effect of peripheral tissues may be caused by inhibiting cyclooxygenase, reducing the formation of prostaglandin precursors, and inhibiting other mediators to induce local inflammatory responses. Flunixin meglumine does not affect gastrointestinal motility in horses, but may improve hemodynamics in animals with septic shock.
Pharmacokinetics: After a single intramuscular injection in pigs (body weight of 2.2mg/kg), the half-life of plasma elimination is 3-4 hours, and the peak concentration is 2.94μg/ml, with a peak time of 0.4 hours. The drug can still be detected in the blood 18 hours after administration. In addition, the apparent distribution volume is 2.0L/kg, and the bioavailability of a single neck injection is 87%.
[Drug Interaction] (1) If this drug is used together with other nonsteroidal anti-inflammatory drugs, it will exacerbate the toxic side effects on the gastrointestinal tract, such as ulcers, bleeding, etc.
(2) Due to the high binding rate of plasma proteins, when used in combination with other drugs, flunixin meglumine may displace other drugs that bind to plasma proteins or be replaced by other drugs, resulting in enhanced effects and even toxicity of the displaced drugs.
[Function and Use] Antipyretic and analgesic anti-inflammatory drug, for small animal fever, inflammatory diseases, muscle pain, and soft tissue pain.
[Dosage and Administration] On the basis of this drug. Oral administration: 40mg/time per 1kg of body weight for dogs and cats, once-twice a day, administered for no more than 5 consecutive days.
[Adverse Reaction] Long term high-dose use of this drug may lead to gastric ulcers and kidney function damage in animals.
[Precautions] For livestock with digestive ulcers, this drug should be used with caution.
[Withdrawal Period] It is not required.
[Specification] 5% on the basis of C14H11F3N2O2
[Package] 1000g/bag × 20bags/carton
[Storage] It should be kept out of light and tightly sealed for storage.
[Shelf Life] 2 years
[Production License No.] (2022) SYSCZZ No. 08019
[GMP Certificate No.] (2022) SY GMP ZZ No. 08010
[Approval No.] SYZ No. 080192104
[Executive Standard] Volume I of Veterinary Pharmacopoeia of the People’s Republic of China (2020 Edition)
